Citi initiates Clovis Oncology at Buy, big upside seen

|About: Clovis Oncology (CLVS)|By:, SA News Editor

Finally, someone on the sell-side is out talking about Clovis Oncology (CLVS) which rallied sharply (then faded a bit) Tuesday on reports it's exploring a sale.

Citi has initiated the shares at Buy.

Price target is $109, representing 45% worth of upside from Thursday's close.

CLVS +2.6% premarket.